About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Humacyte, Inc. - Common Stock (NQ:HUMA)

0.6726 +0.0026 (+0.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Humacyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Trestle Bio Announces Research Collaboration with Humacyte
From Trestle Biotherapeutics, Inc.
Via Business Wire
News headline image
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. is Investigating Humacyte, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Spotlight on Humacyte: Analyzing the Surge in Options Activity ↗
 
Via Benzinga
News headline image
HUMA Deadline: Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Faruqi & Faruqi Reminds Humacyte Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 - HUMA
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Deadline Soon: Humacyte, Inc. (HUMA) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
HUMA DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Wolfspeed, Xerox, Visa, and Humacyte and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
HUMACYTE, INC. (NASDAQ: HUMA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Humacyte, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
HUMACYTE, INC. (NASDAQ: HUMA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Humacyte, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PACS Group, Chipotle, Hasbro, and Humacyte and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Kirby McInerney LLP Urges Investors in Humacyte, Inc. to Inquire About Their Rights in Class Action Lawsuit
From Kirby McInerney LLP
Via Business Wire
News headline image
DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors of Humacyte to Contact Us to Have Their Losses Evaluated Today
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
HUMACYTE, INC. (NASDAQ: HUMA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Humacyte, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Humacyte, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
HUMA Lead Plaintiff Deadline Approaching – Contact Robbins LLP for Information About the Class Action Against Humacyte, Inc.
From Robbins LLP
Via GlobeNewswire
News headline image
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Humacyte, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Microsoft To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
HUMACYTE, INC. (NASDAQ: HUMA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Humacyte, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Dow Surges Over 600 Points, Gold Jumps 1.5% ↗
 
Via Benzinga
Topics Stocks
News headline image
Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher ↗
 
Via Benzinga
News headline image
Mission Produce, Nvidia, Humacyte, BlackBerry And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday? ↗
Humacyte's Symvess earns FDA approval as a first-in-class bioengineered vascular solution for urgent arterial injury repair in trauma cases. 
Via Benzinga
News headline image
Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.